Clinical trial · Interventional
On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software
NCT05666193CI-TRIAL-00085496completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a feasibility study investigating the use of a high-performance HyperSight cone beam CT (CBCT) and adaptive planning software for both online and offline radiotherapy treatment planning for head and neck cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CBCT Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HyperSight Imaging Arm
- description
- Subjects imaged with the new HyperSight CBCT imaging system.
- interventionNames
- Device: CBCT Imaging
Primary outcomes (4)
- measure
- Evaluation of CBCT-based dosimetry calculations
- timeFrame
- 1 day
- description
- The treatment plan calculated on a subject's fan beam simulation CT will be re-calculated on both the HyperSight CBCT acquired on the day of the subject's simulation CT and on the TrueBeam CBCT used for subject positioning during fraction 1 of treatment delivery. Dose-volume histograms for targets and key organs at risk will be compared between the three dose calculations from each subject.
- measure
- Evaluate potential reduction in time and resources required for offline plan adaptation
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient age ≥ 19 2. Patient is scheduled for treatment on one of the five TrueBeam platforms at the NS Health QE2 site. 3. Patient is receiving radiation therapy for cancer of the head and neck involving a target in either the ipsilateral or bilateral neck, with a minimum of 21 fractions. Exclusion Criteria: 1. Patient is pregnant or has plans for pregnancy during the period of treatment. 2. Patient is unwilling to consent to participating to the study, or for whom informed consent is not possible. 3. Patient has previously undergone radiation therapy to the oral cavity or sinuses. 4. Patient has had either a bilateral neck dissection and/or laryngectomy.
References
Publications (0)
Data not yet available
No reference posted for this study.